The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer
Abstract
Interleukin‐6 (IL‐6) is a cytokine, which plays an important role in many chronic inflammatory diseases. IL‐6 belongs to a family of 10 cytokines, which all act via receptor complexes containing the cytokine receptor subunit gp130. On cells, IL‐6 first binds to a specific membrane‐bound IL‐6R and the complex of IL‐6 and IL‐6R interacts with gp130 leading to signal initiation. Whereas gp130 is widely expressed throughout the body, the IL‐6R is only found on some cells including hepatocytes and some leucocytes. A soluble form of the IL‐6R is an agonist capable of transmitting signals through interaction with the gp130 protein. In vivo, the IL‐6/soluble IL‐6R complex stimulates several types of target cells, which are unresponsive to IL‐6 alone, as they do not express the membrane‐bound IL‐6R. We have named this process trans‐signalling. We provided evidence that a soluble form of the IL‐6 family signalling receptor subunit gp130 is the natural inhibitor of IL‐6 trans‐signalling responses. We showed that in chronic inflammatory diseases such as inflammatory bowel disease, peritonitis, rheumatoid arthritis, asthma as well as in colon cancer, IL‐6 trans‐signalling is critically involved in the maintenance of the disease state. Moreover, in all these animal models, the progression of the disease can be interrupted by specifically interfering with IL‐6 trans‐signalling using recombinant‐soluble gp130Fc protein. The pathophysiologic mechanisms by which the IL‐6/soluble IL‐6R complex perpetuates the inflammatory state are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
gp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,461
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationJanssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C., Hammond, A., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S. R., Haugen, H. S., Maurer, M., Harder, B., Johnston, J., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,015
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationNishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 788
Soluble receptors for cytokines and growth factors: generation and biological function
Rose-John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 775
Self-citationHumanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
Self-citationHundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3775 · Cited by 713
Self-citationWSX-1 and Glycoprotein 130 Constitute a Signal-Transducing Receptor for IL-27
Pflanz, S., Hibbert, L., Mattson, J., Rosales, R., Vaisberg, E., Bazan, J. F., Phillips, J. H., McClanahan, T. K., de Waal Malefyt, R., & Kastelein, R. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2225 · Cited by 695
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Self-citationIto, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
Kotake, S., Sato, K., Kim, K. J., Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi, A., Kishimoto, T., Suda, T., & Kashiwazaki, S. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110113 · Cited by 545
Transcriptional profiling identifies Id2 function in dendritic cell development
Hacker, C., Kirsch, R. D., Ju, X.-S., Hieronymus, T., Gust, T. C., Kuhl, C., Jorgas, T., Kurz, S. M., Rose-John, S., Yokota, Y., et al. (2003) · Nature Immunology · doi:10.1038/ni903 · Cited by 544
Self-citationA bioactive designer cytokine for human hematopoietic progenitor cell expansion
Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J. P. G., Kallen, K.-J., Wollmer, A., Grötzinger, J., & Rose-John, S. (1997) · Nature Biotechnology · doi:10.1038/nbt0297-142 · Cited by 530
Self-citationChoy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526 · cited 1×
“The blocking anti-IL-6 receptor antibody MRA (Atlizumab) is highly effective in the treatment of rheumatoid arthritis and Crohn’s disease, and is well tolerated with little adverse reports of infection or toxicity [ 75 ,76].”
BackgroundAbel, S., Hundhausen, C., Mentlein, R., Schulte, A., Berkhout, T. A., Broadway, N., Hartmann, D., Sedlacek, R., Dietrich, S., Muetze, B., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6362 · Cited by 437
Self-citationInterleukin 6 plays a key role in the development of antigen-induced arthritis
Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M., Katada, Y., Tanaka, T., Suemura, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8222 · Cited by 406
Nakahara, H., Song, J., Sugimoto, M., Hagihara, K., Kishimoto, T., Yoshizaki, K., & Nishimoto, N. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11143 · Cited by 395
Perler, F. B. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.344 · Cited by 392
Matthews, V., Schuster, B., Schütze, S., Bussmeyer, I., Ludwig, A., Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.-J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210584200 · Cited by 390 · cited 1×
“Surprisingly, we detected a loss of membrane-bound IL-6R from the cell surface of epithelial cells in tumour lesions, which was accompanied by an increase of cell surface expression of the protease ADAM17, responsible for cleavage of the IL-6R [ 14 ].”
BackgroundSelf-citationDual Oncostatin M (OSM) Receptors
Mosley, B., De Imus, C., Friend, D., Boiani, N., Thoma, B., Park, L. S., & Cosman, D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32635 · Cited by 386
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
Haagmans, B. L., Kuiken, T., Martina, B. E., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan, K.-H., et al. (2004) · Nature Medicine · doi:10.1038/nm1001 · Cited by 381
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins
Mackiewicz, A., Schooltink, H., Heinrich, P. C., & Rose-John, S. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.6.2021 · Cited by 370
Self-citationPerler, F. B. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.383 · Cited by 359
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
McLoughlin, R. M., Jenkins, B. J., Grail, D., Williams, A. S., Fielding, C. A., Parker, C. R., Ernst, M., Topley, N., & Jones, S. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501794102 · Cited by 333
Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22433 · Cited by 333
Self-citationSympathetic neurons can produce and respond to interleukin 6
März, P., Cheng, J.-G., Gadient, R. A., Patterson, P. H., Stoyan, T., Otten, U., & Rose-John, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3251 · Cited by 332
Self-citationMaintenance of Pluripotency in Human Embryonic Stem Cells Is STAT3 Independent
Humphrey, R. K., Beattie, G. M., Lopez, A. D., Bucay, N., King, C. C., Firpo, M. T., Rose‐John, S., & Hayek, A. (2004) · STEM CELLS · doi:10.1634/stemcells.22-4-522 · Cited by 319
Self-citationIsolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A., & Maihle, N. J. (1992) · Cytokine · doi:10.1016/1043-4666(92)90043-q · Cited by 316
Doganci, A., Eigenbrod, T., Krug, N., De Sanctis, G. T., Hausding, M., Erpenbeck, V. J., Haddad, E.-B., Schmitt, E., Bopp, T., Kallen, K.-J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522433 · Cited by 304
Self-citationMcLoughlin, R. M., Witowski, J., Robson, R. L., Wilkinson, T. S., Hurst, S. M., Williams, A. S., Williams, J. D., Rose-John, S., Jones, S. A., & Topley, N. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17129 · Cited by 281 · cited 1×
“Embryonic stem cells [20, 21], early haematopoietic progenitor cells [22–26], T cells [27–29], many neural cells [30, 31], smooth muscle cells [32], mesothelial cells [33, 34 ] and endothelial cells [35], among others, are only responsive to IL-6 in the presence of sIL-6R [18].”
BackgroundSelf-citationDesign of effective immunotherapy for human autoimmunity
Feldmann, M., & Steinman, L. (2005) · Nature · doi:10.1038/nature03727 · Cited by 277
Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis
Peters, M., Müller, A. M., & Rose-John, S. (1998) · Blood · doi:10.1182/blood.v92.10.3495 · Cited by 276
Self-citationCNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK
Watt, M. J., Dzamko, N., Thomas, W. G., Rose-John, S., Ernst, M., Carling, D., Kemp, B. E., Febbraio, M. A., & Steinberg, G. R. (2006) · Nature Medicine · doi:10.1038/nm1383 · Cited by 276
Self-citationPeters, M., Jacobs, S., Ehlers, M., Vollmer, P., Müllberg, J., Wolf, E., Brem, G., Meyer zum Büschenfelde, K. H., & Rose-John, S. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1399 · Cited by 276
Self-citationTreatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.
Wendling, D., Racadot, E., & Wijdenes, J. (1993) · PubMed · Cited by 274
Wong, P. K. K., Quinn, J. M. W., Sims, N. A., van Nieuwenhuijze, A., Campbell, I. K., & Wicks, I. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21537 · Cited by 270
Nowell, M. A., Richards, P. J., Horiuchi, S., Yamamoto, N., Rose-John, S., Topley, N., Williams, A. S., & Jones, S. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3202 · Cited by 268
Self-citationIL-6 Signaling Promotes Tumor Growth in Colorectal Cancer
Becker, C., Fantini, M. C., Wirtz, S., Nikolaev, A., Lehr, H. A., Galle, P. R., John, R., & Neurath, M. F. (2005) · Cell Cycle · doi:10.4161/cc.4.2.1413 · Cited by 255
Review: IL-6 Transsignaling: The In Vivo Consequences
Jones, S. A., Richards, P. J., Scheller, J., & Rose-John, S. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.241 · Cited by 251
Self-citationDelayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice
Sasai, M., Saeki, Y., Ohshima, S., Nishioka, K., Mima, T., Tanaka, T., Katada, Y., Yoshizaki, K., Suemura, M., & Kishimoto, T. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199908)42:8<1635::aid-anr11>3.0.co;2-q · Cited by 227
Southworth, M. W., Amaya, K., Evans, T. C., Xu, M.-Q., & Perler, F. B. (1999) · BioTechniques · doi:10.2144/99271st04 · Cited by 221
Pennica, D., Arce, V, Swanson, T. A., Vejsada, R., Pollock, R. A., Armanini, M., Dudley, K., Phillips, H. S., Rosenthal, A., Kato, A. C., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80281-0 · Cited by 220
Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., Nishibata, T., Kobayashi, K., Okamoto, T., Mukai, Y., Shimizu, T., Nakagawa, S., Nagata, S., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt812 · Cited by 208
The Interleukin-6 Cytokine System Regulates Epidermal Permeability Barrier Homeostasis
Wang, X.-P., Schunck, M., Kallen, K., Neumann, C., Trautwein, C., Rose‐John, S., & Proksch, E. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22736.x · Cited by 205
Self-citationThe role of transsignalling via the agonistic soluble IL-6 receptor in human diseases
Kallen, K.-J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00325-7 · Cited by 205
Klouche, M., Bhakdi, S., Hemmes, M., & Rose-John, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4583 · Cited by 178
Self-citationPeters, M., Schirmacher, P., Goldschmitt, J., Odenthal, M., Peschel, C., Fattori, E., Ciliberto, G., Dienes, H.-P., Büschenfelde, K.-H. M. Z., & Rose-John, S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.755 · Cited by 170
Self-citationNeuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor
Derouet, D., Rousseau, F., Alfonsi, F., Froger, J., Hermann, J., Barbier, F., Perret, D., Diveu, C., Guillet, C., Preisser, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306178101 · Cited by 168
Yoshizaki, K., Nishimoto, N., Mihara, M., & Kishimoto, T. (1998) · Springer Seminars in Immunopathology · doi:10.1007/bf00832010 · Cited by 164
Althoff, K., Reddy, P., Voltz, N., Rose‐John, S., & Müllberg, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01278.x · Cited by 162
Self-citationSignaling of Human Ciliary Neurotrophic Factor (CNTF) Revisited
Schuster, B., Kovaleva, M., Sun, Y. E., Regenhard, P., Matthews, V. B., Grötzinger, J., Rose‐John, S., & Kallen, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210044200 · Cited by 162
Self-citationRobak, T., Gladalska, A., Stepień, H., & Robak, E. (1998) · Mediators of Inflammation · doi:10.1080/09629359890875 · Cited by 161
IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice
Mihara, M., Takagi, N., Takeda, Y., & Ohsugi, Y. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00612.x · Cited by 159
Audet, J., Miller, C., Rose‐John, S., Piret, J. M., & Eaves, C. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1757 · Cited by 158
Self-citationNeural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors
März, P., Otten, U., & Rose‐John, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00755.x · Cited by 147
Self-citationPathological Role of IL-6 in the Experimental Allergic Bronchial Asthma in Mice
Doganci, A., Sauer, K., Karwot, R., & Finotto, S. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:257 · Cited by 142
INTERLEUKIN 6 KNOCK-OUT MICE ARE RESISTANT TO ANTIGEN-INDUCED EXPERIMENTAL ARTHRITIS
Boe, A., Baiocchi, M., Carbonatto, M., Papoian, R., & Serlupi‐Crescenzi, O. (1999) · Cytokine · doi:10.1006/cyto.1999.0502 · Cited by 142
Brakenhoff, J. P. J., Hart, M. H. L., de Groot, E. R., Padova, F. D., & Aarden, L. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.2.561 · Cited by 135
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
Desgeorges, A., Gabay, C., Silacci, P., Novick, D., Roux-Lombard, P., Grau, G. E., Dayer, J. M., VISCHER, T. L., & Guerne, P. A. (1997) · PubMed · Cited by 134
The importance of shedding of membrane proteins for cytokine biology.
Müllberg, J., Althoff, K., Jostock, T., & Rose‐John, S. (2000) · PubMed · Cited by 116
Self-citationSleeman, M. W., Garcia, K., Liu, R., Murray, J. D., Malinova, L., Moncrieffe, M., Yancopoulos, G. D., & Wiegand, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2335926100 · Cited by 115
Rose‐John, S., & Neurath, M. F. (2004) · Immunity · doi:10.1016/s1074-7613(04)00003-2 · Cited by 115
Self-citationPettit, D. K., Bonnert, T. P., Eisenman, J. R., Srinivasan, S., Paxton, R., Beers, C., Lynch, D., Miller, B., Yost, J., Grabstein, K. H., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2312 · Cited by 113
A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation
Rosendahl, M. S., Doherty, D. H., Smith, D. J., Carlson, S. J., Chlipala, E. A., & Cox, G. N. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049713n · Cited by 106
Receptor Recognition Sites of Cytokines Are Organized as Exchangeable Modules
Kallen, K., Grötzinger, J., Lelièvre, E., Vollmer, P., Aasland, D., Renné, C., Müllberg, J., Büschenfelde, K. M. Z., Gascan, H., & Rose‐John, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11859 · Cited by 102
Self-citationKeul, R., Heinrich, P. C., Müller-Newen, G., Muller, K., & Woo, P. (1998) · Cytokine · doi:10.1006/cyto.1997.0343 · Cited by 98
Hochepied, T., Molle, W. V., Berger, F., Baumann, H., & Libert, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.14903 · Cited by 97
No inhibition of IL-27 signaling by soluble gp130
Scheller, J., Schuster, B., Hölscher, C., Yoshimoto, T., & Rose‐John, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.098 · Cited by 74
Self-citationde Hooge, A. S. K., van de Loo, F. A. J., Arntz, O. J., & van den Berg, W. B. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64846-8 · Cited by 74
Shibata, H., Yoshioka, Y., Ikemizu, S., Kobayashi, K., Yamamoto, Y., Mukai, Y., Okamoto, T., Taniai, M., Kawamura, M., Abe, Y., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0770 · Cited by 74
Althoff, K., Müllberg, J., Aasland, D., Voltz, N., Kallen, K., Grötzinger, J., & Rose‐John, S. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530663 · Cited by 70
Self-citationCoordination of interleukin-6 biology by membrane bound and soluble receptors
Rose‐John, S. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0685-0_19 · Cited by 59
Self-citationPflanz, S., Tacken, I., Grötzinger, J., Jacques, Y., Dahmen, H., Heinrich, P. C., & Müller‐Newen, G. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00477-9 · Cited by 58
Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency
Yoshioka, Y., Tsutsumi, Y. M., Ikemizu, S., Yamamoto, Y., Shibata, H., Nishibata, T., Mukai, Y., Okamoto, T., Taniai, M., Kawamura, M., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.125 · Cited by 52
GP130 stimulation and the maintenance of stem cells
Rose‐John, S. (2002) · Trends in biotechnology · doi:10.1016/s0167-7799(02)02056-5 · Cited by 47
Self-citationMitsuyama, K., Tomiyasu, N., Suzuki, A., Takaki, K., Takedatsu, H., Masuda, J., Yamasaki, H., Matsumoto, S., Tsuruta, O., Toyonaga, A., et al. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02960.x · Cited by 34
A New Type of Cytokine Receptor Antagonist Directly Targeting gp130
Renné, C., Kallen, K., Müllberg, J., Jostock, T., Grötzinger, J., & Rose‐John, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27213 · Cited by 34
Self-citationSemisynthesis and Application of Carboxyfluorescein-Labelled Biologically Active Human Interleukin-8
David, R., Machova, Z., & Beck‐Sickinger, A. G. (2003) · Biological Chemistry · doi:10.1515/bc.2003.180 · Cited by 29
Campard, D., Vasse, M., Rose‐John, S., Poyer, F., LAMACZ, M., & Vannier, J. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0173 · Cited by 28
Self-citationThe effect of gp130 stimulation on glutamate-induced excitotoxicity in primary hippocampal neurons
Sun, Y. E., März, P., Otten, U., Ge, J., & Rose‐John, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00706-4 · Cited by 25
Self-citationNew perspectives on the design of cytokines and growth factors
Kallen, K., Grötzinger, J., & Rose‐John, S. (2000) · Trends in biotechnology · doi:10.1016/s0167-7799(00)01492-x · Cited by 25
Self-citationTsunoda, S., Ishikawa, T., Watanabe, M., Kamada, H., Yamamoto, Y., Tsutsumi, Y. M., Hirano, T., & Mayumi, T. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02508.x · Cited by 21
Aasland, D., Schuster, B., Grötzinger, J., Rose‐John, S., & Kallen, K. (2003) · Biochemistry · doi:10.1021/bi0263311 · Cited by 15
Self-citationFunctionally active fusion protein of the novel composite cytokine CLC/soluble CNTF receptor
Guillet, C., Lelièvre, E., Plun‐Favreau, H., Froger, J., Chabbert, M., Hermann, J., de Coignac, A. B., Bonnefoy, J., Gascan, H., Gauchat, J., et al. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02850.x · Cited by 14
Atreya, R. N., Finotto, S., Mudter, J., Mullberg, J., Jostock, T., Holtmann, M. H., Kishimoto, T., Galle, P. R., Rose‐John, S., & Neurath, M. F. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)85593-6 · Cited by 12
Self-citationRose‐John, S. (2006) · Handbook of experimental pharmacology · doi:10.1007/3-540-31265-x_10 · Cited by 7
Self-citation
Cited by
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Interleukin 6: from bench to bedside
Nishimoto, N., & Kishimoto, T. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0338 · Cited by 642
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Metadata
- Authors
- Scheller, J., Ohnesorge, N., & Rose‐John, S.
- Venue
- Scandinavian Journal of Immunology
- Publisher
- Wiley
- Published
- 2006-04-25
- Volume
- 63
- Issue
- 5
- Pages
- 321-329
- ISSN
- 0300-9475 (ISSN-L)
- 1365-3083
- OpenAlex
- W2099731425
- Cited by
- 297
- References
- 94
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.